Hee Min Noh is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s patents and innovations group. Hee Min advises biotechnology and pharmaceutical companies focusing on patent prosecution and intellectual property counseling in the areas of therapeutic antibodies, antibody drug conjugates, antibody oligonucleotide conjugates, RNA therapeutics, and cell therapy. Her expertise includes patent prosecution, global patent portfolio development and management, due diligence, and patentability and freedom-to-operate analyses. She also assists clients with IP matters in various transactions, such as financings, M&A, licenses, and public offerings.
Prior to joining the firm, Hee Min worked as a Korean patent attorney at IP law firms in South Korea. She prosecuted domestic and foreign patent applications and advised clients on patentability, invalidity, infringement, and freedom-to-operate issues. In addition, she litigated patents before the Korean Patent Court and prepared a technical analysis in a patent infringement case before the Supreme Court of Korea.
Hee Min is fluent in Korean and Japanese.
Hee Min Noh is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s patents and innovations group. Hee Min advises biotechnology and pharmaceutical companies focusing on patent prosecution and intellectual property counseling in the areas of therapeutic antibodies, antibody drug conjugates, antibody oligonucleotide conjugates, RNA therapeutics, and cell therapy. Her expertise includes patent prosecution, global patent portfolio development and management, due diligence, and patentability and freedom-to-operate analyses. She also assists clients with IP matters in various transactions, such as financings, M&A, licenses, and public offerings.
Prior to joining the firm, Hee Min worked as a Korean patent attorney at IP law firms in South Korea. She prosecuted domestic and foreign patent applications and advised clients on patentability, invalidity, infringement, and freedom-to-operate issues. In addition, she litigated patents before the Korean Patent Court and prepared a technical analysis in a patent infringement case before the Supreme Court of Korea.
Hee Min is fluent in Korean and Japanese.
- J.D., University of California College of the Law, San Francisco
- B.S., Biochemistry, Yonsei University
- State Bar of California
- U.S. Patent and Trademark Office
- J.D., University of California College of the Law, San Francisco
- B.S., Biochemistry, Yonsei University
- State Bar of California
- U.S. Patent and Trademark Office
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Biochemistry
- Bioconjugation
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell therapy
- Cellular immunology
- Immuno-oncology
- Immunobiology
- Immunology
- MicroRNA (miRNA) research
Therapeutics and Drug Discovery
- Antimicrobial agents
- Drug conjugates
- Drug conjugates based drug discovery
- Drug delivery
- Gene therapy
- Immunotherapy targets
- Peptide therapeutics
- RNA interference (RNAi)
Diagnostics and Medical Devices
- Diagnostics
- Medical devices
- miRNA detection
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Biochemistry
- Bioconjugation
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell therapy
- Cellular immunology
- Immuno-oncology
- Immunobiology
- Immunology
- MicroRNA (miRNA) research
Therapeutics and Drug Discovery
- Antimicrobial agents
- Drug conjugates
- Drug conjugates based drug discovery
- Drug delivery
- Gene therapy
- Immunotherapy targets
- Peptide therapeutics
- RNA interference (RNAi)
Diagnostics and Medical Devices
- Diagnostics
- Medical devices
- miRNA detection
Under the terms of the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to Sirius. The companies will jointly develop SRSD107—a next-generation, long-acting Factor XI (FXI) siRNA for the treatment of thromboembolic disorders—under a 50-50 cost and profit-sharing structure. CRISPR Therapeutics will lead commercialization in the U.S., while Sirius will be responsible for commercialization in Greater China. Additionally, CRISPR Therapeutics will have the option to nominate up to two siRNA targets for research and development. For each target, CRISPR Therapeutics will fund research and retain opt-in rights to lead clinical development and commercialization. Sirius will be eligible to receive milestone payments, as well as tiered royalties ranging from high-single to low-double digits.
The Wilson Sonsini team that advised Sirius on patent matters related to the transaction was led by Minyoung Shin and included Mike Hostetler, Hee Min Noh, Jen Zeng, and Tiara Wong.
For more information, please see the companies’ news release. Additional coverage is available in Fierce Biotech and BioSpace.
- Privacy Policy
- Terms of Use
- Accessibility